New radioactive drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07505771
First seen Apr 02, 2026 · Last updated May 03, 2026 · Updated 7 times
Summary
This early-phase study tests a new radioactive drug, 177Lu-IM-3050, in about 105 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. Participants receive the drug and are monitored for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Excel Diagnostics and Nuclear Oncology Center
RECRUITINGHouston, Texas, 77042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.